Navigation Links
Telik Announces Telintra Clinical Presentations at the Annual Meeting of the American Society of Hematology
Date:11/10/2011

PALO ALTO, Calif., Nov. 10, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) announced today two clinical presentations at the 53rd Annual Meeting of the American Society of Hematology in San Diego, California. Details of the presentations are as follows:

  • Phase 1 Dose-Ranging Study of Oral Ezatiostat Hydrochloride (Telintra®, TLK199) in Combination with Lenalidomide (Revlimid®) in Patients with Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS); Azra Raza, MD; Naomi Galili, PhD; Deborah Mulford, MD; Scott E. Smith, MD, PhD, FACP; Gail Brown, MD; Lisa Meng, PhD; David P. Steensma, MD; Roger M Lyons, MD; Ralph Boccia, MD; Mikkael A. Sekeres, MD, MS; Guillermo Garcia-Manero, MD; and Ruben A. Mesa, MD
    • Abstract #2778 – Myelodysplastic Syndromes: Poster II; Sunday, December 11, 2011, 6:00 PM -8:00 PM; San Diego Convention Center, Hall GH
  • Gene Expression Studies May Identify Lower Risk Myelodysplastic Syndrome Patients Likely to Respond to Therapy with Ezatiostat Hydrochloride (TLK199); Naomi Galili, Ph.D.; Pablo Tamayo, PhD; Olga B Botvinnik; Jill P Mesirov, PhD; Jennifer Zikria, MD; Gail Brown, MD and Azra Raza, MD
    • Abstract #2779 – Myelodysplastic Syndromes: Poster II; Sunday, December 11, 2011, 6:00 PM - 8:00 PM; San Diego Convention Center, Hall GH

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The company's most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic malignancies including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.

Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Telik Announces Third Quarter 2011 Financial Results
2. Telik Announces Publication of a Report of Complete Response of G-CSF Resistent Severe Idiopathic Chronic Neutropenia Following Treatment with Telintra®
3. Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
4. Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome
5. Telik Announces Publication in the Journal Cancer of a Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome
6. Telik Announces First Quarter 2011 Financial Results
7. Telik Announces Presentation of New Data on the Characterization of Novel Ezatiostat (TELINTRA®, TLK199) Analogs at American Association for Cancer Research Annual Meeting
8. Telik Announces Presentation and Webcast at 10th Annual Needham Healthcare Conference
9. Telik Announces Fourth Quarter and 2010 Year End Financial Results and 2011 Financial Guidance
10. Telik Announces Presentation and Webcast at 13th Annual BIO CEO & Investor Conference
11. Telik Announces Presentation at American Society of Hematology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Florida , January 19, 2017 ... Trump administration appears serious about reducing the FDA,s ... and innovation in the medical drug industry, many ... ahead with new clinical trials and development of ... companies forging ahead with recent developments include:  Moleculin ...
(Date:1/19/2017)... The Global Therapy Partnering Terms and Agreements since 2010 ... agreements entered into by the world,s leading healthcare companies. ... by value - Deals listed by company A-Z, industry ... provides understanding and access to the partnering deals and ... The report provides an analysis of partnering deals. ...
(Date:1/19/2017)... ALEXANDRIA, Va. , Jan. 18, 2017 /PRNewswire/ ... commends the Food and Drug Administration (FDA) for ... biopharmaceutical companies and population health decision makers can ... FDA approved products as well as emerging therapies ... guidance largely mirrors consensus recommendations that AMCP developed ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... Ultimate Medical Academy ... who are passionate about making a difference in the lives of the next ... UMA, a nonprofit healthcare educational institution, has more than 30,000 alumni and employs ...
(Date:1/19/2017)... Ashland, VA (PRWEB) , ... January 19, 2017 , ... ... planning services to the eastern Virginia region, is inaugurating a charity event to honor ... community. , While on duty last year, Chad Phillip Dermyer and his fellow officers ...
(Date:1/19/2017)... ... 19, 2017 , ... Creative messages to prevent distracted driving ... Impact Teen Drivers and California Casualty. Entries from students aged 14-22 can be ... $15,000 will be awarded for the best peer-to-peer messages sharing solutions to reckless ...
(Date:1/19/2017)... ... January 19, 2017 , ... Connecticut Dermatology Group (CDG) is proud and ... and compassionate dermatologist. Dr. Kim brings an extensive background in cutting-edge dermatology care ... considerable pleasure to welcome back Dr. Kim to the CDG team” said President and ...
(Date:1/19/2017)... ... , ... Infinity® Massage Chairs announced today that Dan Grover has joined the ... Grover comes with a total of 15 years experience in consumer goods and an ... President of Direct Sales at Traeger® Wood Pellet Grills. , Grover has elevated ...
Breaking Medicine News(10 mins):